- Home
- NEWT vs CYRX Comparison
NEWT vs CYRX Comparison
Compare NEWT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | CYRX |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 421.6M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NEWT | CYRX |
|---|---|---|
| Price | $11.73 | $7.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $14.00 | $12.94 |
| AVG Volume (30 Days) | 162.5K | ★ 367.2K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $9.71 |
| Revenue Next Year | $12.45 | $9.56 |
| P/E Ratio | $5.99 | ★ $5.72 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.12 | $4.63 |
| 52 Week High | $14.91 | $11.45 |
Technical Indicators
Market Signals| Indicator | NEWT | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 34.81 |
| Support Level | $11.72 | $6.57 |
| Resistance Level | $12.41 | $7.88 |
| Average True Range (ATR) | 0.47 | 0.45 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 15.17 | 8.57 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.